Regulatory pathway · all topics

Breakthrough Device Designation

Breakthrough Device Designation under 21 USC 360e-3 expedites development and review of devices providing more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. Benefits include interactive review, senior management engagement, prioritized review, and Medicare coverage pathway. As of FY2024, FDA had granted over 1,000 designations. Designation must be requested separately and does not lower evidence standards.

Source

FDA, 'Breakthrough Devices Program' (21 USC 360e-3)

https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

How MedTek OS handles this

Compass drafts the breakthrough device designation workflow with confidence-gated content.

The platform refuses to generate content below the threshold for this artifact class. Every claim carries a citation chain back to RIG, audit-logged with HMAC integrity.

Try the sandbox Ask the agent about this

Related pathways

510(k) Premarket Notification

A 510(k) clearance under 21 CFR Part 807 Subpart E demonstrates substantial equivalence to a legally marketed predicate device. Required for...

De Novo Classification Request

De Novo creates a new classification for a novel low-to-moderate risk device with no valid predicate. Submission under 21 CFR Part 860 Subpa...

Premarket Approval (PMA)

PMA is the most stringent FDA pathway, required for Class III devices that support or sustain human life or pose significant risk. Filed und...

Investigational Device Exemption (IDE)

An IDE under 21 CFR Part 812 allows an unapproved device to be used in a clinical study to gather safety and effectiveness data. Required wh...